Medlab Group

Medlab Clinical is an Australian biotechnology company that specialized in the development of pharmaceutical-grade cannabinoid therapeutics and innovative drug delivery systems. The company's core technology is the NanoCelle platform, a patented delivery system that creates sub-micron sized particles for transmucosal administration, bypassing the gastrointestinal tract to improve bioavailability and speed of onset. Its lead candidate, NanaBis, is a standardized CBD/THC formulation delivered via NanoCelle, primarily targeted at managing bone pain in cancer patients. Medlab also developed NanoCBD for chronic pain and stress, alongside a pipeline of programs for mental health and metabolic disorders. Following financial challenges, the company entered voluntary administration in early 2023 and subsequently delisted from the Australian Securities Exchange, with its core assets being restructured or sold.